Abstract: The invention provides intravascular devices for treating certain medical conditions such as edema without causing thrombosis. The intravascular devices of the disclosure include non-thrombogenic surfaces that improve blood compatibility by reducing device-related thrombus formation and inflammatory reactions. The non-thrombogenic surfaces may include surface topographies (e.g., surface roughness) and modified chemistries (e.g., coatings and/or treatments), which prevent thrombosis by reducing local shear forces and inhibiting adhesion of blood clotting factors.

Abstract: A tissue engineering scaffold for cell, tissue or organ growth comprises a biocompatible porous polyurethane cellular material comprising a plurality of substantially spherical voids of diameter from 20 to 300 microns, preferably 80 to 200 microns, interconnected by generally elliptically shaped pores. The cellular material has a void content of from 85% to 98% and a surface area to volume of from 5 to 400 mm2/mm3, ideally from 20 to 80 mm2/mm3.

Abstract: An embolic protection system comprises an embolic protection filter 1 having a collapsed delivery configuration and an expanded deployed configuration. The filter 1 is housed in the collapsed configuration in a reception space of a delivery catheter 20. The delivery catheter 20 containing the filter 1 is housed in a sealed sterile pouch 35. The filter 1 may be coated with a non-thrombogenic coating and an adhesion preventer 9 such as a silicon gel is used to substantially prevent adhesion of adjacent folds of the filter 1 when the filter is in the collapsed configuration in the delivery catheter 20.

Abstract: An embolic protection system comprises an embolic protection filter 1 having a collapsed delivery configuration and an expanded deployed configuration. The filter 1 is housed in the collapsed configuration in a reception space of a delivery catheter 20. The delivery catheter 20 containing the filter 1 is housed in a sealed sterile pouch 35. The filter 1 may be coated with a non-thrombogenic coating and an adhesion preventer 9 such as a silicon gel is used to substantially prevent adhesion of adjacent folds of the filter 1 when the filter is in the collapsed configuration in the delivery catheter 20.

Abstract: A tissue engineering scaffold for cell, tissue or organ growth comprises a biocompatible porous polyurethane cellular material comprising a plurality of substantially spherical voids of diameter from 20 to 300 microns, preferably 80 to 200 microns, interconnected by generally elliptically shaped pores. The cellular material has a void content of from 85% to 98% and a surface area to volume of from 5 to 400 mm2/mm3, ideally from 20 to 80 mm2/mm3.

Abstract: An embolic protection system comprises an embolic protection filter 1 having a collapsed delivery configuration and an expanded deployed configuration. The filter 1 is housed in the collapsed configuration in a reception space of a delivery catheter 20. The delivery catheter 20 containing the filter 1 is housed in a sealed sterile pouch 35. The filter 1 may be coated with a non-thrombogenic coating and an adhesion preventer 9 such as a silicon gel is used to substantially prevent adhesion of adjacent folds of the filter 1 when the filter is in the collapsed configuration in the delivery catheter 20.

Abstract: A tissue engineering scaffold for cell, tissue or organ growth comprises a biocompatible porous polyurethane cellular material comprising a plurality of substantially spherical voids of diameter from 20 to 300 microns, preferably 80 to 200 microns, interconnected by generally elliptically shaped pores. The cellular material has a void content of from 85% to 98% and a surface area to volume of from 5 to 400 mm2/mm3, ideally from 20 to 80 mm2/mm3.

Abstract: A biocompatible polymeric material is prepared by forming a three dimensional cross-linked structure of a biocompatible polymeric material such as a polyether or polycarbonate polyurethane and solvent extracting the material with a swelling solvent such as MEK which swells the material by up to 150%. The solvent swollen polymeric material is then de-swelled with a non solvent such as water which is miscible with the extraction solvent. The process produces polymeric materials which do not produce leachables and thereby have properties that are suitable for implantation.

Abstract: A biostable porous polyether or polycarbonate polyurethane implant is manufactured from diphenyl methane diisocyanate, difunctional polytetramethylene ether glycol or a polycarbonate polyol, a trimerisation catalyst, a chain extender, water, a cross-linking agent, a blowing and/or gelling catalyst and a surfactant. The porous biomaterial has isocyanurate linkages and avoid content in excess of 85%. The implant may be used as an occluder or a tissue bridge.